Sangamo Therapeutics Newsroom

Sangamo Therapeutics Is Maintained at Overweight by Barclays

Dow JonesNov 14 09:24 ET

Sangamo Therapeutics Analyst Ratings

BenzingaNov 14 09:14 ET

TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating

Moomoo NewsNov 14 08:31 ET

H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsNov 14 08:31 ET

A Quick Look at Today's Ratings for Sangamo Therapeutics(SGMO.US), With a Forecast Between $3 to $10

Moomoo NewsNov 14 08:06 ET

Wells Fargo Gives a Hold Rating to Sangamo Biosciences (SGMO)

TipRanksNov 14 04:54 ET

Sangamo Therapeutics Analyst Ratings

BenzingaNov 5 08:24 ET

H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Raises Target Price to $10

Moomoo NewsNov 5 06:37 ET

Truist Financial Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating

Moomoo NewsOct 24 06:41 ET

TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating

Moomoo NewsOct 24 01:32 ET

A Quick Look at Today's Ratings for Sangamo Therapeutics(SGMO.US), With a Forecast Between $1 to $5

Moomoo NewsOct 23 09:09 ET

Sangamo Therapeutics Analyst Ratings

BenzingaOct 22 12:27 ET

Sangamo Therapeutics Analyst Ratings

BenzingaAug 22 09:07 ET

H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsAug 22 06:33 ET

RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)

TipRanksAug 7 07:28 ET

Sangamo Therapeutics Analyst Ratings

BenzingaJul 31 08:39 ET

H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsJul 31 06:33 ET

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target

BenzingaJul 24 15:23 ET

Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know

BenzingaMay 15 11:04 ET

Sangamo Therapeutics Analyst Ratings

BenzingaMay 15 10:34 ET